Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma, including the first relapse setting. In the MajesTEC-9 trial, ...
Izalontamab brengitecan (iza-bren) is an antibody-drug conjugate and bispecific antibody undergoing evaluation in small cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results